Cover Image
Market Research Report

Age Related Macular Degeneration - Pipeline Review, H2 2017

Published by Global Markets Direct Product code 213105
Published Content info 537 Pages
Immediate Delivery Available
Price
Back to Top
Age Related Macular Degeneration - Pipeline Review, H2 2017
Published: December 29, 2017 Content info: 537 Pages
Description

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Age Related Macular Degeneration - Pipeline Review, H2 2017, provides an overview of the Age Related Macular Degeneration (Ophthalmology) pipeline landscape.

Age related macular degeneration is the most common reason for vision loss in people aged above 50. It results in depreciation of the macula that may lead to distorted or blurry central vision. The predisposing factors involved are age, smoking, sunlight, heredity etc. Symptoms include development of blind spot and hazy vision. The condition may be treated by photodynamic therapy, radiation therapy and medication such as anti-angiogenic drugs.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Age Related Macular Degeneration - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Age Related Macular Degeneration (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Age Related Macular Degeneration (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Age Related Macular Degeneration and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 7, 27, 18, 4, 135, 29 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 16 and 2 molecules, respectively.

Age Related Macular Degeneration (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Age Related Macular Degeneration (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Age Related Macular Degeneration (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Age Related Macular Degeneration (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Age Related Macular Degeneration (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Age Related Macular Degeneration (Ophthalmology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Age Related Macular Degeneration (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Age Related Macular Degeneration (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Product Code: GMDHC10032IDB

Table of Contents

  • Table of Contents
  • Introduction
  • Age Related Macular Degeneration - Overview
  • Age Related Macular Degeneration - Therapeutics Development
  • Age Related Macular Degeneration - Therapeutics Assessment
  • Age Related Macular Degeneration - Companies Involved in Therapeutics Development
  • Age Related Macular Degeneration - Drug Profiles
  • Age Related Macular Degeneration - Dormant Projects
  • Age Related Macular Degeneration - Discontinued Products
  • Age Related Macular Degeneration - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Age Related Macular Degeneration, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Age Related Macular Degeneration - Pipeline by 3SBio Inc, H2 2017
  • Age Related Macular Degeneration - Pipeline by Abzena Plc, H2 2017
  • Age Related Macular Degeneration - Pipeline by Achillion Pharmaceuticals Inc, H2 2017
  • Age Related Macular Degeneration - Pipeline by Aciont Inc, H2 2017
  • Age Related Macular Degeneration - Pipeline by Acucela Inc, H2 2017
  • Age Related Macular Degeneration - Pipeline by AdAlta Ltd, H2 2017
  • Age Related Macular Degeneration - Pipeline by Adverum Biotechnologies Inc, H2 2017
  • Age Related Macular Degeneration - Pipeline by Aerie Pharmaceuticals Inc, H2 2017
  • Age Related Macular Degeneration - Pipeline by Aerpio Therapeutics Inc, H2 2017
  • Age Related Macular Degeneration - Pipeline by Alimera Sciences Inc, H2 2017
  • Age Related Macular Degeneration - Pipeline by Alkeus Pharmaceuticals Inc, H2 2017
  • Age Related Macular Degeneration - Pipeline by Allergan Plc, H2 2017
  • Age Related Macular Degeneration - Pipeline by Allgenesis Biotherapeutics Inc, H2 2017
  • Age Related Macular Degeneration - Pipeline by Allinky Biopharma, H2 2017
  • Age Related Macular Degeneration - Pipeline by Alteogen Inc, H2 2017
  • Age Related Macular Degeneration - Pipeline by Amarna Therapeutics BV, H2 2017
  • Age Related Macular Degeneration - Pipeline by Apellis Pharmaceuticals Inc, H2 2017
  • Age Related Macular Degeneration - Pipeline by Apexigen Inc, H2 2017
  • Age Related Macular Degeneration - Pipeline by Applied Genetic Technologies Corp, H2 2017
  • Age Related Macular Degeneration - Pipeline by Ascentage Pharma Group Corp Ltd, H2 2017
  • Age Related Macular Degeneration - Pipeline by Astellas Pharma Inc, H2 2017
  • Age Related Macular Degeneration - Pipeline by Benitec Biopharma Ltd, H2 2017
  • Age Related Macular Degeneration - Pipeline by Biokine Therapeutics Ltd, H2 2017
  • Age Related Macular Degeneration - Pipeline by BioMAS Ltd, H2 2017
  • Age Related Macular Degeneration - Pipeline by Biomics Biotechnologies Co Ltd, H2 2017
  • Age Related Macular Degeneration - Pipeline by Biophytis SAS, H2 2017
  • Age Related Macular Degeneration - Pipeline by Caladrius Biosciences Inc, H2 2017
  • Age Related Macular Degeneration - Pipeline by Catalyst Biosciences Inc, H2 2017
  • Age Related Macular Degeneration - Pipeline by Cell Cure Neurosciences Ltd, H2 2017
  • Age Related Macular Degeneration - Pipeline by Cell Medica Ltd, H2 2017
  • Age Related Macular Degeneration - Pipeline by Charlesson LLC, H2 2017
  • Age Related Macular Degeneration - Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2017
  • Age Related Macular Degeneration - Pipeline by CJ HealthCare Corp, H2 2017
  • Age Related Macular Degeneration - Pipeline by Clanotech AB, H2 2017
  • Age Related Macular Degeneration - Pipeline by Coherus BioSciences Inc, H2 2017
  • Age Related Macular Degeneration - Pipeline by Colby Pharmaceutical Co, H2 2017
  • Age Related Macular Degeneration - Pipeline by Crinetics Pharmaceuticals Inc, H2 2017
  • Age Related Macular Degeneration - Pipeline by Daiichi Sankyo Co Ltd, H2 2017
  • Age Related Macular Degeneration - Pipeline by Diffusion Pharmaceuticals Inc, H2 2017
  • Age Related Macular Degeneration - Pipeline by Dong-A Socio Holdings Co Ltd, H2 2017
  • Age Related Macular Degeneration - Pipeline by Eleven Biotherapeutics Inc, H2 2017
  • Age Related Macular Degeneration - Pipeline by Elsalys Biotech SAS, H2 2017
  • Age Related Macular Degeneration - Pipeline by Enzene Biosciences Ltd, H2 2017
  • Age Related Macular Degeneration - Pipeline by Exonate Ltd, H2 2017
  • Age Related Macular Degeneration - Pipeline by EyeGate Pharmaceuticals Inc, H2 2017
  • Age Related Macular Degeneration - Pipeline by Eyevensys SAS, H2 2017
  • Age Related Macular Degeneration - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
  • Age Related Macular Degeneration - Pipeline by FirstString Research Inc, H2 2017
  • Age Related Macular Degeneration - Pipeline by Foamix Pharmaceuticals Ltd, H2 2017
  • Age Related Macular Degeneration - Pipeline by Formycon AG, H2 2017
  • Age Related Macular Degeneration - Pipeline by Gene Techno Science Co Ltd, H2 2017
  • Age Related Macular Degeneration - Pipeline by Genentech Inc, H2 2017
  • Age Related Macular Degeneration - Pipeline by GenSight Biologics SA, H2 2017
  • Age Related Macular Degeneration - Pipeline by Graybug Vision Inc, H2 2017
  • Age Related Macular Degeneration - Pipeline by HanAll Biopharma Co Ltd, H2 2017
  • Age Related Macular Degeneration - Pipeline by Huabo Biopharm Co Ltd, H2 2017
  • Age Related Macular Degeneration - Pipeline by Icon Bioscience Inc, H2 2017
  • Age Related Macular Degeneration - Pipeline by Iconic Therapeutics Inc, H2 2017
  • Age Related Macular Degeneration - Pipeline by Ildong Pharmaceutical Co Ltd, H2 2017
  • Age Related Macular Degeneration - Pipeline by Inception Sciences Inc, H2 2017
  • Age Related Macular Degeneration - Pipeline by Innovent Biologics Inc, H2 2017
  • Age Related Macular Degeneration - Pipeline by Intellect Neurosciences Inc, H2 2017
  • Age Related Macular Degeneration - Pipeline by Ionis Pharmaceuticals Inc, H2 2017
  • Age Related Macular Degeneration - Pipeline by Jeil Pharmaceutical Co Ltd, H2 2017
  • Age Related Macular Degeneration - Pipeline by Johnson & Johnson, H2 2017

List of Figures

  • Number of Products under Development for Age Related Macular Degeneration, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Top 10 Routes of Administration, H2 2017
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2017
  • Number of Products by Top 10 Molecule Types, H2 2017
  • Number of Products by Stage and Top 10 Molecule Types, H2 2017
Back to Top